33 results about "Chickenpox" patented technology

Disclosed are an mRNA vaccine encoding a varicella zoster virus (VZV) protein, a preparation method therefor, and use thereof. The mRNA vaccine is characterized by encoding at least the varicella zoster virus (VZV) gE protein, gH protein, and gL protein.

The application discloses a kind of enveloped virus inactivation preparation based on medium-chain triglyceride and application thereof, the present application relates to the technical field of biological medicine external preparation, including active ingredient and auxiliary material: the active ingredient includes: high-purity medium-chain triglyceride (MCT), preferably octanoic acid (C8) and capric acid (C10) triglyceride mixture, purity ≥99%; The auxiliary material includes: food-grade antioxidant, for preventing oxidation of preparation, the content of food-grade antioxidant is 0.01-0.05%w / w, with medium-chain triglyceride as active ingredient, through the physical and chemical synergistic effect, enveloped virus is efficiently killed, for treating stubborn skin mucosa infection diseases (such as stubborn flat warts, herpes labialis, genital herpes, etc.) caused by human papillomavirus (HPV), herpes simplex virus (HSV-1 / HSV-2), varicella-zoster virus and other enveloped viruses.

Provided are a primer-probe combination for real-time quantitative PCR, a related kit, and a method for using primers to measure the titers of measles, mumps and varicella virus pathogens. The method is applicable to clinical and laboratory detection, is fast and convenient, and has high sensitivity.

The invention discloses an immunogenic composition containing gE nanoparticles as well as a preparation method and application thereof, and relates to the technical field of biomedicine, the immunogenic composition comprises self-assembled gE nanoparticles and an oil-in-water emulsion adjuvant, and a self-assembled gE nanoparticle antigen comprises gE, a connecting peptide SGS and a gI polypeptide sequence containing Th epitopes; the oil-in-water type emulsion adjuvant is prepared from squalene, Tween 80, DL-alpha-tocopherol and / or Span 85. The immunogenic composition provided by the invention can be applied to vaccines for preventing varicella and / or herpes zoster and / or postherpetic neuralgia, so that the aims of improving the immunogenicity of the gE antigen and reducing side effects of the vaccines are fulfilled.

The invention discloses a gE fusion protein containing a gH Th epitope and a preparation method and application thereof, and relates to the technical field of biomedicine, the fusion protein comprises a varicella-zoster virus (VZV) glycoprotein E extracellular domain (gE) and a Th epitope-containing VZV glycoprotein H extracellular domain (gH) polypeptide. The gE fusion protein can be applied to VZV vaccines, and solves the technical problems of weak immunogenicity of gE antigens and serious side reaction of vaccines in vaccines prepared in the prior art. Compared with the Xinanlietaine, the vaccine taking the gE fusion protein as the antigen has the advantages that the variety and dosage of immunopotentiators are less, the immunogenicity is better, and the clinical side reaction is lower; besides, the gE fusion protein vaccine not only can induce a gE specific CMI reaction, but also can induce a gH specific CMI reaction, so that the effectiveness of the vaccine is further improved. In short, the gE fusion protein has good clinical application potential.

Various nucleoside phosphate and phosphonate analogues are provided for treatment of viral infections. Methods of preparing the analogues, pharmaceutical compositions containing the analogues, and methods of using the analogues as antiviral compounds, especially against adenoviruses, coronaviruses, and varicella zoster viruses, are also provided.

Embodiments of the present disclosure generally relate to a new class of compositions that include VZV IE62 or a derivative thereof (e.g., a mutant) and lipid particles. Embodiments of the present disclosure also relate to uses of the compositions for treating, alleviating, or reducing the severity of, various diseases or medical conditions in a patient. For example, embodiments described herein may be utilized for treating, alleviating, or reducing the severity of various neuroinflammation and related pathologies and diseases such as psoriasis, rheumatoid arthritis, systemic lupus erythematosus, ulcerative colitis, multiple sclerosis, neuromyelitis optica, or dementia, among others.

The present application relates to the field of immunological detection, and particularly relates to a reagent for detecting varicella-zoster virus infection and a preparation method thereof. The reagent comprises R1 reagent and R2 reagent; the R1 reagent is a working solution of streptavidin magnetic beads, and the preparation method comprises the following steps: firstly coupling activated carboxyl magnetic beads with streptavidin; dialyzing the magnetic beads obtained by the first coupling to remove streptavidin physically combined with the magnetic beads; secondly coupling the dialyzed magnetic beads with streptavidin; quenching the magnetic beads obtained by the second coupling, and then placing the magnetic beads in a working solution to obtain the working solution; the working solution contains fetal bovine serum, bovine serum albumin and lysine; the R2 reagent is a biotinylated VZV gE recombinant protein, and the VZV gE recombinant protein is a varicella-zoster virus gE glycoprotein extracellular domain fragment expressed by human embryonic kidney cells. The reagent has high sensitivity and specificity in the detection of varicella-zoster virus infection.

The present application relates to the technical field of biological medicine, in particular to a preparation method of varicella attenuated live vaccine, a freeze-drying protective agent and application thereof, which comprises the steps of cell culture, virus infection, complex enzymatic dissociation, protective ultrasonic disruption, clarification and collection, etc. The complex enzymatic dissociation adopts EDTA and recombinant trypsin combination to loosen the cells at low temperature; the protective ultrasonic disruption adopts a buffer solution containing trehalose and recombinant human blood albumin to resuspend the cells and perform intermittent ultrasonic disruption. The present application further provides a freeze-drying protective agent which is composed of trehalose, sorbitol, L-arginine, L-histidine and polyvinylpyrrolidone. The virus harvesting efficiency of the method is high, and the virus activity loss is small; the freeze-drying protective agent has good safety and excellent stability.

The application discloses a plant-expressed varicella-zoster virus gB recombinant antigen and a preparation method, product and application thereof, and belongs to the technical field of plant molecular biology and vaccine engineering. The technical problems to be solved are that the existing VZV gB protein has low heterologous expression, poor stability and insufficient antigen activity; the existing VZV vaccine has high production cost, is difficult to popularize and has a single antigen with an immune escape risk; and the plant expression system is not mature in VZV gB antigen production, and lacks a complete preparation scheme and related products. The technical solution is that the natural VZV gB protein is modified, a furin protease cleavage site is knocked out, and a H527P mutation is introduced, related nucleic acid molecules, vectors and plant source cells are constructed, high-activity antigens are obtained through culture and purification, and the high-activity antigens are applied to the preparation of VZV drugs / vaccines, and have the advantages of low cost, high safety and strong immunogenicity.

This invention relates to the field of biomedical technology, specifically to a stabilized and modified herpes zoster virus gE protein, its preparation method, and its applications. The stabilized and modified herpes zoster virus gE protein of this invention is obtained through cysteine ​​mutation modification and structural design optimization, and exhibits improved expression levels, thermal stability, and immunogenicity compared to recombinant varicella-zoster virus gE protein with only the removal of the carboxyl-terminal hydrophobic transmembrane region and intracellular tail.

The application belongs to the technical field of biological detection, and particularly relates to an isothermal amplification detection reagent and kit for detecting varicella-zoster virus (VZV). The application designs a specific primer pair with a target of a conservative region of an ORF62 of a VZV genome, performs RPA reaction, combines a modified detection probe, and uses lateral flow chromatography test paper to realize a detection sensitivity of not higher than 1 copy / µL for a crude extract of a vesicle fluid or throat swab sample, realize rapid and high-sensitivity detection, and has good popularization and application value.

The invention discloses self-assembled gE nanoparticles as well as a preparation method and application thereof, and relates to the technical field of biomedicine. The self-assembled gE nanoparticle is formed by polymerizing a plurality of monomers, and the monomers comprise a varicella-zoster virus gE and a varicella-zoster virus gI polypeptide containing a Th epitope. The self-assembled gE nanoparticles provided by the invention can be applied to VZV vaccines, and solves the technical problems of weak gE immunogenicity and serious vaccine side reaction in vaccines prepared in the prior art. Compared with the Xinanlietaine, the vaccine taking the self-assembled gE nano-particle as the antigen has the advantages that the variety and dosage of an immunopotentiator are less, the immunogenicity is better, and the clinical side reaction is lower; besides, the self-assembled gE nanoparticle vaccine not only can induce a gE specific CMI reaction, but also can induce a gI specific CMI reaction, so that the effectiveness of the vaccine is further improved. In a word, the self-assembled gE nanoparticles have good clinical application potential.

The application discloses a kind of detection varicella-zoster virus LAMP-CRISPR reaction tube, kit and method, belong to biological detection technical field.The application provides a kind of detection varicella-zoster virus LAMP-CRISPR reaction tube, the reaction tube includes the LAMP reaction system freeze-dried microspheres placed in the bottom of pipe, and the CRISPR detection system freeze-dried powder sprayed on the pipe cover;The LAMP reaction system includes the LAMP primer group of nucleic acid sequence such as SEQ ID NO:2~7;The CRISPR detection system includes the crRNA of nucleic acid sequence such as SEQ ID NO:8.The LAMP-CRISPR reaction tube of the application uses "one-step method" single-tube closed-tube operation, only needs to be added to LAMP-CRISPR reaction tube after sample processing can carry out detection, and detection result is specific, and sensitivity is high.

The present application relates to the technical field of biological medicine, in particular to a kind of stable modified varicella-zoster virus gE protein, its preparation method and application.The stable modified varicella-zoster virus gE protein of the present application is obtained by cysteine mutation modification and structure design optimization, compared with the recombinant varicella-zoster virus gE protein with only carboxy-terminal hydrophobic transmembrane region and intracellular tail removed, has improved expression, thermal stability and immunogenicity.

The present disclosure provides a vaccine against herpes zoster, the herpes zoster vaccine comprising or encoding a varicella zoster virus (VZV) antigen, capable of eliciting an effective neutralizing antibody response against varicella zoster virus (VZV).

The present invention provides novel variants of varicella-zoster virus gE protein, mRNA vaccines encoding the gE variants or gE variant fusion proteins. The mRNA vaccine based on the gE variant or the gE variant fusion protein can induce high-level IgG antibody reaction, T cell immune response and T cell immune memory.

Provided herein are varicella-zoster virus vaccine, human papillomavirus vaccine, and Rabies vaccine antigens, compositions thereof, and uses thereof in cancer immunotherapy and cancer treatment.

The application discloses a medicine composition for treating viral herpes skin diseases and a preparation method thereof, and belongs to the technical field of medicines. The medicine composition comprises 1 part of Myristica, 2 parts of Banlangen, 2 parts of Lianqiao, 1 part of Huangqin, 3 parts of Daqingye, 2 parts of Danzhuye, 3 parts of Zixueye, 1 part of Niu Douzi, 2 parts of Gegen, 1 part of Beiqiehu, 1 part of Guanghuoxiang, 1 part of Pailan, 1 part of Shichangpu and 1 part of Chuanqiong. The composition can effectively treat herpes skin diseases caused by different pathogens such as hand-foot-mouth disease, chickenpox and herpes zoster, and has a broad spectrum of prevention and treatment effects.

The invention provides a non-natural nucleic acid, a genetic engineering vector, a host cell, a delivery vector, a pharmaceutical composition and application thereof, and a VZV (varicella zoster virus) vaccine. The non-natural nucleic acid comprises polynucleotide encoding VZV gE protein or a fragment thereof.

Provided are a vaccine composition for Varicella Zoster virus (VZV) including a glycoprotein E (gE) antigen of VZV and monophosphoryl lipid A (MLA), and a method of using the same. The vaccine composition according to an aspect of the invention may significantly improve a production yield by including the gE antigen having an optimized signal peptide sequence, may enhance immunogenicity by including MLA, and may further enhance the immunogenicity enhanced by MLA by further adding saponin such as QS-21, and may be prepared in a form of CoPoP liposomes so that vaccine antigens may be presented on the surface of the liposomes for better absorption by antigen-presenting cells, and vaccine efficacy may be maximized by inclusion of the vaccine antigens and immune adjuvants in a formulation. Therefore, the vaccine composition may be useful as an alternative to current vaccines in the art for prevention or treatment of VZV infection.

The application discloses a method for screening antiviral target points by targeting viral DNA, and effective sgRNA sequences targeting key DNA regions of varicella-zoster virus, herpes simplex virus type I and Kaposi's sarcoma-associated herpes virus are obtained respectively; dCas9-sgRNA containing viral DNA plasmid is co-transfected, and DNA of the varicella-zoster virus, the herpes simplex virus type I and the Kaposi's sarcoma-associated herpes virus is immunoprecipitated and enriched respectively to screen proteins regulating viral replication; the proteins are identified by mass spectrometry, and it is verified that the method is also applicable to screening proteins regulating viral replication by targeting HIV DNA, so that the method for screening proteins regulating viral replication by targeting viral DNA is established.

The invention discloses an antibody for resisting varicella-zoster virus and application of the antibody. A heavy chain variable region of the antibody comprises HCDR1, HCDR2 and HCDR3 which are respectively shown as SEQ ID NO: 42 to 44, SEQ ID NO: 7 to 9, SEQ ID NO: 13 to 15, SEQ ID NO: 19 to 21, SEQ ID NO: 30 to 32 or SEQ ID NO: 36 to 38; and / or the light chain variable region of the antibody comprises LCDR1, LCDR2 and LCDR3 as shown in SEQ ID NO: 45, 5 and 46, SEQ ID NO: 10 to 12, SEQ ID NO: 16 to 18, SEQ ID NO: 22 to 24, SEQ ID NO: 33 to 35 or SEQ ID NO: 39 to 41 respectively. The neutralizing effect IC50 value of the antibody on the VZV virus can reach 0.18 mu g / mL.

The present application relates to compositions capable of inducing an immune response against Varicella zoster virus, methods of administering such compositions, and methods of producing such compositions.

The invention discloses gE nanoparticles as well as a preparation method and application thereof. The gE nanoparticles are formed by polymerizing a plurality of monomers; the monomer comprises a varicella-zoster virus gE and a varicella-zoster virus gI polypeptide containing a Th epitope. The immunogenicity of the gE nanoparticles provided by the invention is superior to that of gE, the preparation method is simple, the gE nanoparticles can be applied to varicella-zoster virus vaccines, and the technical problems that the immunogenicity of the gE is relatively weak and the side reaction of the vaccines is serious in the preparation of the vaccines in the prior art are solved. Compared with the Xinanlietaine, the vaccine taking the gE nano-particle as the antigen has the advantages that the variety and the dosage of an immunopotentiator are less, the immunogenicity is better, and the clinical side reaction is lower; besides, the vaccine not only can induce a gE specific CMI reaction, but also can induce a gI specific CMI reaction, so that the effectiveness of the vaccine is further improved. The gE nanoparticles have good clinical application potential.

Provided herein are fragments of the gE protein of varicella-zoster virus and therapeutic nucleic acid molecules for the management, prevention, and / or treatment of diseases or disorders caused by varicella-zoster virus or infection thereof. Also provided herein are therapeutic compositions comprising vaccines and lipid nanoparticles containing therapeutic nucleic acids, as well as related therapeutic methods and uses.

Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include at least one RNA polynucleotides having a open reading frame encoding at least varicella zoster virus (VZV) antigen. Methods for preparing and using such vaccines are also described.

The invention discloses an LAMP-CRISPR reaction tube, a kit and a method for detecting varicella-zoster virus, and belongs to the technical field of biological detection. The invention provides an LAMP-CRISPR reaction tube for detecting varicella-zoster virus. The LAMP-CRISPR reaction tube comprises LAMP reaction system freeze-dried microspheres arranged at the bottom of the tube and CRISPR detection system freeze-dried powder sprayed on a tube cover, the LAMP reaction system comprises an LAMP primer group of which the nucleotide sequence is as shown in SEQ ID NO: 2-7; the CRISPR detection system comprises crRNA (Ribonucleic Acid) of which the nucleotide sequence is shown as SEQ ID NO: 8. According to the LAMP-CRISPR reaction tube disclosed by the invention, a'one-step method 'single-tube closed tube operation is adopted, a sample can be detected only by adding the sample into the LAMP-CRISPR reaction tube after being treated, and a detection result is strong in specificity and high in sensitivity.